Evercore ISI has recently raised Crispr Therapeutics AG (CRSP) stock rating, as announced on February 14, 2025, according to Finviz. Earlier, on February 12, 2025, TD Cowen had raised the stock from a Sell to Hold, setting a price target of $35. H.C. Wainwright also initiated Buy rating with a price target of $65. Additionally, Needham reiterated Buy rating on August 6, 2024, with a target price of $84. Rodman & Renshaw analysts, in their report published on August 2, 2024, also initiated Buy rating and set a price target of $90 for Crispr Therapeutics AG’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Crispr Therapeutics AG (CRSP) Stock Trading Recap
On Tuesday, Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $42.37 which represents a decrease of $-0.97 or -2.24% from the prior close of $43.34. The stock opened at $42.93 and touched a low of $40.82 during the day, reaching a high of $43.34. The volume of shares traded was 1.98 million falling short of the average volume of 2.19 million.
Sponsored
CRSP Stock Performance and Moving Averages
In recent trading, Crispr Therapeutics AG (CRSP) stock price has shown some volatility, fluctuating -2.49% over the last five trades and 6.70% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -5.04%, and it has plunged by -14.42% in the previous three months. Currently, CRSP is trading at -6.56%, -0.78%, and -13.15% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CRSP, a Healthcare sector stock, is trading -46.59% below its 52-week high but remains 16.02% above its 52-week low. The Average True Range (ATR) (14 days) of 2.92 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Crispr Therapeutics AG’s Profitability and Valuation Ratios
Crispr Therapeutics AG’s profitability metrics reveal financial health. The company currently boasts an operating margin of -1250.38% and a profit margin of -981.54%, with a gross margin of -5.04%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Crispr Therapeutics AG’s market capitalization stands at $3.63 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 97.41, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.88, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 4.32% of Crispr Therapeutics AG (CRSP)’s shares, while financial institutions hold 69.38%.
Notable insider trades include Kulkarni Samarth, Chief Executive Officer at Crispr Therapeutics AG (CRSP), who sold 18,360 shares on Feb 19 ’25, at $55.20 each, totaling $1.01 million. On Feb 18 ’25, Kulkarni Samarth, Chief Executive Officer, sold 11,640 shares for $55.05 each, amounting to $0.64 million. Additionally, on Feb 19 ’25, Kulkarni Samarth sold 6,928 shares at $52.80 each, generating $0.37 million.
